Analysts Anticipate Healthequity Inc (HQY) Will Post Quarterly Sales of $68.79 Million

Equities research analysts predict that Healthequity Inc (NASDAQ:HQY) will post sales of $68.79 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Healthequity’s earnings. The highest sales estimate is $70.12 million and the lowest is $67.61 million. Healthequity reported sales of $55.42 million in the same quarter last year, which indicates a positive year-over-year growth rate of 24.1%. The company is expected to announce its next earnings results on Tuesday, June 5th.

According to Zacks, analysts expect that Healthequity will report full-year sales of $281.11 million for the current year, with estimates ranging from $278.74 million to $284.80 million. For the next financial year, analysts forecast that the business will post sales of $341.72 million per share, with estimates ranging from $336.40 million to $348.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Healthequity.

How to Become a New Pot Stock Millionaire

Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Monday, March 19th. The company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Healthequity had a net margin of 20.64% and a return on equity of 13.47%. The business had revenue of $60.44 million for the quarter, compared to analysts’ expectations of $58.46 million.

Several research analysts have recently issued reports on HQY shares. Citigroup started coverage on shares of Healthequity in a report on Thursday, January 4th. They issued a “buy” rating on the stock. BidaskClub upgraded shares of Healthequity from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. JPMorgan Chase cut their target price on shares of Healthequity from $52.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, January 24th. Chardan Capital raised their target price on shares of Healthequity from $62.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 20th. Finally, Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating and set a $62.00 target price on the stock. in a report on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Healthequity presently has an average rating of “Buy” and an average target price of $66.50.

NASDAQ HQY traded down $0.87 on Friday, reaching $65.32. 344,740 shares of the company’s stock traded hands, compared to its average volume of 655,227. Healthequity has a 12 month low of $40.21 and a 12 month high of $68.75. The stock has a market capitalization of $4,028.32, a P/E ratio of 120.98, a PEG ratio of 2.65 and a beta of 1.39.

In other Healthequity news, CEO Jon Kessler sold 1,332 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $55.00, for a total transaction of $73,260.00. Following the completion of the transaction, the chief executive officer now owns 446,332 shares of the company’s stock, valued at $24,548,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jon Soldan sold 995 shares of the firm’s stock in a transaction on Wednesday, March 28th. The shares were sold at an average price of $61.30, for a total value of $60,993.50. Following the transaction, the vice president now directly owns 9,433 shares of the company’s stock, valued at approximately $578,242.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 750,831 shares of company stock worth $40,420,618. 29.00% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in HQY. Catalyst Capital Advisors LLC purchased a new position in Healthequity during the fourth quarter valued at $149,000. Two Sigma Securities LLC purchased a new position in Healthequity during the fourth quarter valued at $208,000. Exane Derivatives lifted its position in Healthequity by 78.6% during the fourth quarter. Exane Derivatives now owns 4,682 shares of the company’s stock valued at $218,000 after buying an additional 2,060 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Healthequity during the fourth quarter valued at $220,000. Finally, Envestnet Asset Management Inc. purchased a new position in Healthequity during the third quarter valued at $273,000. 99.17% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/20/analysts-anticipate-healthequity-inc-hqy-will-post-quarterly-sales-of-68-79-million.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply